Mineralys Therapeutics Quarterly Cash Flow Statement
NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
23.37+0.99 (+4.42%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mineralys Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Mineralys Therapeutics generated -$32.6 million of operating cash flow. That left free cash flow of -$32.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Mineralys Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -241.07M | -39.34M | -32.23M | -36.93M | -43.27M | -42.21M | -48.95M | -56.34M | -41.01M | -31.51M | -24.39M | -22.76M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 5.00K | 6.00K | 13.00K | 15.00K | 16.00K | 15.00K | 15.00K | 11.00K | 9.00K | 8.00K | 0 | 0 |
| Stock-Based Compensation | 7.36M | 6.55M | 5.29M | 5.84M | 4.55M | 3.65M | 3.13M | 3.14M | 2.87M | 2.19M | 1.46M | 1.58M |
| Change in Working Capital | 5.63M | -2.35M | -6.56M | 4.59M | 10.81M | -5.94M | -19.81M | 5.70M | 10.65M | 12.56M | -4.28M | 4.33M |
| Operating Cash Flow | -32.56M | -39.47M | -37.89M | -28.87M | -30.17M | -45.49M | -66.84M | -50.19M | -30.15M | -19.14M | -28.98M | -19.03M |
| Capital Expenditures | — | — | -15.00K | 0 | 0 | 0 | 0 | -37.00K | 0 | -59.00K | 0 | 0 |
| Investing Cash Flow | -185.22M | -44.94M | -103.49M | -150.51M | -42.88M | -92.88M | 83.57M | 79.61M | 7.74M | -55.95M | -8.09M | 4.01M |
| Financing Cash Flow | 243.26M | 24.27M | 96.70M | 295.19M | 9.83M | 189.28M | 90.00K | -1.00K | -152.00K | 116.20M | 74.00K | 184.00K |
| Net Change in Cash | 25.49M | -60.14M | -44.68M | 115.81M | -63.22M | 50.92M | 16.82M | 29.42M | -22.56M | 41.11M | -37.00M | -14.84M |
| Free Cash Flow | -32.56M | -39.47M | -37.90M | -28.87M | -30.17M | -45.49M | -66.84M | -50.22M | -30.15M | -19.20M | -28.98M | -19.03M |
This table shows 12 quarterly periods of Mineralys Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MLYS's reporting calendar. What is a cash flow statement?